Monte Rosa Therapeutic (GLUE) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 11, 2026, with voting and Q&A available online for registered shareholders.

• Shareholders will vote on electing three Class II directors and ratifying Deloitte & Touche LLP as the independent auditor for 2026.

• Proxy materials are distributed electronically to reduce costs and environmental impact, with printed copies available upon request.

• Only shareholders of record as of April 16, 2026, are entitled to vote at the meeting.

Voting matters and shareholder proposals

• Proposal 1: Election of three Class II directors (Andrew Schiff, Chandra Leo, Anthony Manning) for terms expiring in 2029.

• Proposal 2: Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Shareholders may submit proposals for the 2027 meeting by December 30, 2026, or nominate directors under SEC universal proxy rules.

• Board recommends voting FOR all director nominees and auditor ratification.

Board of directors and corporate governance

• Board consists of nine members divided into three staggered classes, with diverse backgrounds in medicine, finance, and biotech.

• All directors except the CEO are considered independent under Nasdaq and SEC rules.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, each with defined charters and independent membership.

• Directors are encouraged to attend annual meetings and adhere to a code of business conduct and insider trading policy.